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Mutations in the Myosin VIIA Gene Cause a Wide
Phenotypic Spectrum, Including Atypical Usher
Syndrome
To the Editor:
Usher syndrome (USH) is the most common recessive
syndromic hearing loss characterized by congenital hear-
ing impairment associated with retinitis pigmentosa
(RP). It is a clinically and genetically heterogeneous con-
dition. Three clinical forms of USH have been described,
and seven loci have been mapped (Hereditary Hearing
Loss home page). The three types are distinguished by
the severity and progression of the hearing impairment
and by the presence of vestibular disaffection. USH1 is
the most severe form and is manifested by profound
congenital deafness, constant vestibular dysfunction,
and RP of prepubertal onset. USH2 includes congenital
moderate to severe hearing loss, normal vestibular re-
sponses, and RP. A third group of patients have been
classified, in whom hearing loss is progressive and there
are variable vestibular problems as well as RP. Patients
in this class have been described as USH3 (Sankila et al.
1995), although, for some families, in the absence of any
clear genetic distinction from other USH classifications,
such individuals generally may be best classified as hav-
ing an atypical USH phenotype. Five USH1 loci, USH
1A–1E, have been mapped to chromosome bands
14q32, 11q13.5, 11p15, 10q, and 21q21, respectively
(Hereditary Hearing Loss home page). A locus for USH3
has been localized to chromosome 3q21-25 in Finnish
families with an USH3 phenotype (Sankila et al. 1995).
USH1B is encoded by the MYO7A gene (Weil et al.
1995), and recently a variety of mutations leading to
USH1B have been reported and catalogued in the
MYO7A gene (Weston et al. 1996; Liu et al. 1997a;
Levy et al. 1997; Adato et al. 1997; Hasson 1997). We
now report that mutations in the MYO7A gene can lead
to atypical USH.
Seven families (six from the United Kingdom and one
from China) were identified as having atypical USH phe-
notypes similar to that of USH3. They were examined
for MYO7A mutations, by a combined SSCP/hetero-
duplex analysis method (Liu et al. 1997a). In family
USH3.04, originating from England, the parents were
unaffected and had two affected children (fig. 1a). Pa-
tient II.1 (39 years old) had a bilateral progressive hear-
ing loss with onset at age 2 years. She remembered hear-
ing well until age ∼14 years (hearing thresholds in all
frequencies were at 55–60 dB hearing level [HL]). Since
then, she has required the use of hearing aids and her
hearing thresholds have fallen to 90 dB HL, and even-
tually audiograms showed nonrecordable thresholds
when she was age 29 years. She has normal speech and
normal caloric responses. RP was diagnosed at age 38
years when she saw an ophthalmologist, since her
brother had then been diagnosed with USH. Ophthal-
moscopy showed typical but mild pigmentary degener-
ation, with bone spicules and arteriolar attenuation. The
electroretinogram was mildly reduced, and visual fields
were moderately constricted. Patient II.2 was found to
have hearing loss at age 18 mo, with progression from
moderate to severe loss. His speech is quite good. RP
was diagnosed at age of 15 years. Further details of
clinical evaluation of this family have been reported by
Hope et al. (1997). Thus, the condition in this family
with atypical USH is most closely related to USH3.
This family was tested for cosegregation of the disease
with previously mapped USH3 and USH1B loci, by
means of polymorphic markers specific for each locus
(Hereditary Hearing Loss home page). According to the
segregation analysis of the marker haplotypes (data not
shown), the segregation of the disease in this family was
not consistent with the involvement of the previously
identified USH3 locus on chromosome 3. However, hap-
lotype analysis did indicate that results for this family
were consistent with linkage to the USH1B locus—the
two affected sibs shared identical genotypes in the
USH1B region, with differing paternal and maternal
haplotypes inherited. Moreover, SSCP analysis of exons
17 and 35 in MYO7A (Levy et al. 1997) in this family
demonstrated patterns different than those in 60 normal
controls (fig. 1b). Sequence analysis of the SSCP variants
revealed that both affected sibs were compound heter-
ozygotes, with a Leu651Pro substitution in exon 17 in
one allele, inherited from their mother, and an
Arg1602Gln mutation in exon 35 in the other allele,
inherited from their father (fig. 1c). Both mutations are
believed to be pathological, first because of their location
and conservation (see below) and, second, because nei-
ther change has been observed in a series of normal
controls.
The mutation Leu651Pro in exon 17 lies within a
crucial region in the lower 50-kD subdomain of the my-
osin head. This region contains the largest number of
conserved residues in the motor domain and is believed
to maintain structural integrity of the head domain
(Cope et al. 1996). Alignment of known myosin motor
domains shows that the altered leucine residue is con-
served among a large number of myosin sequences (Cope
et al. 1996). Interestingly, the residue is 1 of 10 amino
acids deleted (del645–655) in the mouse shaker1 allele,
sh1816SB (Mburu et al. 1997) (fig. 2). This deletion re-
moves part of the a-helix in a highly mobile region that
is thought to be involved in the transduction of energy
from the site of ATP hydrolysis to the regulatory domain.
The identification of two pathological mutations in the
same region in separate species suggests a vital function.
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Figure 1 Analysis of family USH3.04. a, Pedigree. b, SSCP patterns of exons 17 (left panel) and 35 (right panel) of MYO7A (primers
are from Levy et al. [1997]). For exon 17, a heterozygous variant (lower and upper bands) can be seen in lanes 2, 3, and 5 (patients II.1 and
II.2 and patients’ mother [I.2], respectively); results for a normal control and the patients’s father (I.1) (upper band) also are shown, in lanes
1 and 4, respectively. For exon 35, a heterozygous variant (lower and upper bands) can be seen in lanes 2, 3, and 5 (patients II.1 and II.2 and
patients’ father [I.1]); results for a normal control and the patients’s mother (I.2) (upper band) also are shown, in lanes 1 and 4, respectively.
c, Direct sequence analysis of control and patient II.1, for exon 17. Left panel, Results for patient II.1, who shows a heterozygous CrT
substitution (as does II.2 [data not shown]). The mother (I.2) is heterozygous for the mutation (data not shown). Right panel, Direct sequence
analysis of exon 35 from the control and patient II.1, with the latter showing a heterozygous GrA substitution (as does II.2 [data not shown]).
The father (I.1) is heterozygous for the mutation (data not shown).
The Arg1602Gln mutation in exon 35 occurs in a residue
that is conserved in mouse and human and that lies at
the C-terminal boundary of a MYO7A tail long direct
repeat that, in both human and mouse (Chen et al. 1996;
Mburu et al. 1997), shows homology to both a plant
kinesin tail domain and members of the band 4.1 family,
as well as to regions of other myosin tails (myosins IV,
X, and XII). MYO7A may have the properties of a my-
osin motor-kinesin tail hybrid and may be involved with
membrane turnover in the actin-rich environment of the
apical hair-cell surface (Mburu et al. 1997). The plant
kinesin and band 4.1 domains in the tail may be im-
portant for the interaction of MYO7A with membranes
or membrane-associated proteins. Interestingly, the
Arg1602Gln substitution in the atypical USH family also
has been identified in patients with USH1B (Weston et
al. 1998).
Genetically, USH is quite heterogeneous. Our data
also show that atypical USH and USH3 are apparently
genetically heterogeneous, with mutations at different
loci, on 3q and 11q, in different families. In addition,
it also is clear that mutations at the same locus,MYO7A,
can give rise to both USH1, in which there is severe to
profound hearing loss, and atypical USH, in which the
hearing loss is progressive. Most important, the
Arg1602Gln mutation identified in the atypical USH
family that we have studied also has been found in pa-
tients with USH1B (Weston et al. 1998). Given both the
likely severity of the nonconservative Leu651Pro change
in the atypical USH family and the finding that, in some
individuals, the Arg1602Gln allele can lead to severe
USH1B, the data provide the first evidence suggesting
that genetic background may be important in determin-
ing the severity of USH.
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Figure 2 Spectrum of MYO7A mutations that lead to USH1B (Weston et al. 1996, 1998; Adato et al. 1997; Levy et al. 1997; Liu et al.
1997a) and atypical USH syndromic deafness (present study), as well as recessive (i.e., DFNB2 [Liu et al. 1997b; Weil et al. 1997]) and dominant
(i.e., DFNA11 [Liu et al. 1997c]) nonsyndromic deafness. The positions of seven shaker1 mutant alleles are also shown (below) (Mburu et al.
1997), and the various homology domains in the MYO7A tail are indicated (Chen et al. 1996; Mburu et al. 1997).
MYO7A also recently has been shown to harbor mu-
tations causing both recessive (DFNB2 [Liu et al. 1997b;
Weil et al. 1997]) and dominant (DFNA11 [Liu et al.
1997c]) nonsyndromic deafness. When the data reported
here are considered, it is now clear that different mu-
tations in MYO7A can lead to a wide range of pheno-
types, including both syndromic USH1B and atypical
USH, as well as both nonsyndromic recessive (DFNB2)
and nonsyndromic dominant (DFNA11) deafness (fig.
2). With the exception of the DFNA11 mutation, there
does not appear to be a clear correlation between mu-
tation and phenotype. The DFNA11 mutation is a 9-bp
in-frame deletion in the coiled-coil region of MYO7A
(Liu et al. 1997c), which is thought to be responsible
for dimerization of the molecule (fig. 2). Mutations in
the coiled-coil region may result in dominant hearing
loss due to a dominant-negative effect. Indeed, unlike
individuals with the other three forms of hearing loss
caused by MYO7A mutations, DFNA11 patients have
a less severe postlingual hearing loss (Liu et al. 1997c).
In three DFNB2 families with MYO7A mutations re-
ported to date, profound deafness with variable vestib-
ular dysfunction is a constant phenotype. However, one
of these families, which is from Tunisia, demonstrates a
mutation that is known to decrease the efficiency of
splicing, and affected members show a variable age at
onset of deafness (Weil et al. 1997). Patients in the other
two DFNB2 families, which are from China, have con-
genital profound deafness (Liu et al. 1997b).
There are many instances whereby different mutations
in the same gene can result in diverse phenotypes (Ro-
meo and McKusick 1994). Allelic heterogeneity can ac-
count for markedly different phenotypes. MYO7A mu-
tations in human can lead to either an isolated inner-ear
lesion, as in mouse shaker1 mutations, or a combined
inner-ear and retinal pathology. It is possible that, in
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human, tissue-specific differences in the function of
MYO7A might result in specific mutations having dif-
ferent effects in the eye but similar effects in the inner
ear. It seems likely, however, given (a) the wide range of
MYO7A mutations identified for both nonsyndromic
deafness and USH and (b) the results reported in the
present study, that genetic background effects have some
role to play in determining the development and severity
of nonsyndromic and syndromic hearing loss.
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Haplotype Analysis in Icelandic Families Defines a
Minimal Interval for the Macular Corneal Dystrophy
Type I Gene
To the Editor:
Macular corneal dystrophy (MCD [MIM 217800]) is a
rare autosomal recessive disorder that is clinically char-
